HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Lowers Price Target to $11

Benzinga · 3d ago
HC Wainwright & Co. analyst Matthew Keller maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and lowers the price target from $31 to $11.